Sort by
Refine Your Search
-
Country
-
Field
-
the expectation that you will be able to write protocols, contribute to the design of experimental plans and develop new scientific techniques. It is essential that you hold a PhD/DPhil (or close to completion) in
-
, safety, gene therapy, DNA repair Principal Investigator: Marta Olejniczak, PhD, professor of IBCH PAS Research topic: “Assessing efficacy and safety of genome EDITing approaches for Sickle Cell Disease
-
experimental plans and develop new scientific techniques. It is essential that you hold a PhD/DPhil (or close to completion) in protein crystallography/structural biology, or a related subject together
-
Physics, Cambridge Image Analysis (CIA) Group), clinical practice (Dr Tim Rittman, Clinical Neuroscience) with healthcare innovation (Eastern AHSN) and pharmaceutical industry partners (AstraZeneca). Our
-
Physics, Cambridge Image Analysis (CIA) Group), clinical practice (Dr Tim Rittman, Clinical Neuroscience) with healthcare innovation (Eastern AHSN) and pharmaceutical industry partners (AstraZeneca). Our
-
to apply for the EACR-AstraZeneca Postdoctoral Fellowship, for which no more than 8 years can have elapsed since the Ph.D. defence. However, the lab has secured funding for at least 1 year, so the selected
-
, safety, gene therapy, DNA repair Principal Investigator: Marta Olejniczak, PhD, Associate Professor of IBCH PAS Research topic: “Assessing efficacy and safety of genome EDITing approaches for Sickle Cell